ALS (motor neurone disease): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TDP-43 8
• SOD1 7
• C9orf72 4
• NRF2 0
• STING 0
• SIRT1 0
• HDAC 0
• NLRP3 0
• TREM2 0
• BDNF 0
• MAPK 0
• APOE 0
• GLP-1 0
• HMGB1 0
• mTOR 0
• SMN1 0
• TP53 0
• AMPK 0
• BTK 1
• CXCR4 0
• HSP90 1
• JAK 0
• JNK 0
• LAG-3 0
• NMDA 0
• PI3K 0
• PINK1 0
• PPAR 0
• TFEB 0
• TNF 0
• AKT 0
• APP 0
• ATM 0
• AXL 0
• BCL-2 0
• CDK4/6 0
• COX-2 0
• CSF1R 0
• ERK 0
• GPX4 0
• IL-1 0
• MAPT 0
• PARP 0
• PCSK9 0
• PDE4 1
• PSEN1 0
• PTEN 0
• SNCA 0
• STK11 0
• TLR4 0
• TTR 0
• VEGF 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

  NCT01459302· University of Massachusetts, Worcester· Updated 19 Sept 2024

  “This study is not a clinical trial.”Registry text, quoted unchanged. Source

• Suspended

  SOD1 Kinetics Measurements in ALS Patients

  NCT03449212· Washington University School of Medicine· Updated 25 Jul 2024

  “COVID-19 pandemic”Registry text, quoted unchanged. Source

• Withdrawn

  Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05949294· Arrowhead Pharmaceuticals· Updated 17 Apr 2024

  “Company business decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

  NCT04856982· Biogen· Source

• First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

  NCT06351592· Regeneron Pharmaceuticals· Source

• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

  NCT07223723· Biogen· Source

• iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

  NCT04744532· Kyoto University· Source

• A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

  NCT07259980· Biogen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 7
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 8
• Gene Expression Profiling 23
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 6
• Proteomics 29
• Metabolomics 7
• Mass Spectrometry 6
• Flow Cytometry 2
• Immunohistochemistry 5
• Liquid Biopsy 2
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 57
• Machine Learning 18
• Deep Learning 7
• Cohort Studies 79
• Genome-Wide Association Study 24

• Mapping high resolution, multidimensional phase diagrams of near-physiological protein condensates.

  Nat Commun, Sept 2026

• Identifying candidate therapeutic targets in amyotrophic lateral sclerosis through a transcriptome-wide machine-learning consensus approach for drug repurposing.

  Neuroscience, Aug 2026

• Identification of Glycolysis-Related Diagnostic Biomarkers for Amyotrophic Lateral Sclerosis Using Machine Learning.

  Clin Lab, Aug 2026

• Identification of Reliable Biomarkers for ALS Through Machine Learning Approach.

  Stud Health Technol Inform, May 2026

• WBT-DC pipeline: a cross-cohort and cross-platform disease classification pipeline based on whole-blood transcriptomics.

  J Transl Med, May 2026

• Unveiling an ALS Blood Transcriptomic Signature: A Machine Learning Classifier Distinct from Neurodegenerative Controls.

  Neuroinformatics, Apr 2026

• Smart Sensor-Driven Gait Rehabilitation Walker Using Machine Learning for Predictive Home-Based Therapy.

  Sensors (Basel), Apr 2026

• Physiological predictors of respiratory motor plasticity: A machine-learning reappraisal of phrenic motor facilitation.

  Respir Physiol Neurobiol, Apr 2026

• Development of a machine learning-based survival prediction model for ALS inclusive of the advanced-stage population.

  Amyotroph Lateral Scler Frontotemporal Degener, Apr 2026

• Exploring the feasibility of near-infrared spectroscopy and machine learning for detecting cardiovascular diseases and diabetes mellitus in fingernails.

  Analyst, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.